' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells.
Harrer, A; Wipfler, P; Einhaeupl, M; Pilz, G; Oppermann, K; Hitzl, W; Afazel, S; Haschke-Becher, E; Strasser, P; Trinka, E; Kraus, J;
J Neuroimmunol. 2011; 234(1-2):148-154
Originalarbeiten (Zeitschrift)


Harrer Andrea
Haschke-Becher Elisabeth
Hitzl Wolfgang
Kraus Jörg
Oppermann Katrin
Pilz Georg
Strasser Peter
Trinka Eugen
Wipfler Peter


Natalizumab interferes with immune cell migration into the central nervous system via blocking the alpha-4 subunit of very-late activation antigen-4 (VLA-4). Occurrence of rare but serious progressive multifocal leukoencephalopathy during prolonged natalizumab therapy of multiple sclerosis (MS) calls for a more detailed understanding of potential coeffects. We longitudinally studied alpha-4 and beta-1 surface levels on blood cells from 18 MS patients by flow cytometry. Expectedly, detectability of natalizumab-blocked alpha-4 was diminished on all investigated cell subsets. In addition, we report a concurrent and significant decrease of beta-1 surface levels on T-cells, B-cells, natural killer cells, and natural killer T cells, but not on monocytes. Uncovering secondary effects of natalizumab is mandatory to increase safety in MS therapy.

Useful keywords (using NLM MeSH Indexing)


Antibodies, Monoclonal/therapeutic use*

Antibodies, Monoclonal, Humanized

Antigens, CD/genetics

Antigens, CD/metabolism


Flow Cytometry/methods

Gene Expression Regulation/drug effects

Gene Expression Regulation/physiology*


Integrin alpha4beta1/genetics

Integrin alpha4beta1/metabolism*

Leukocytes, Mononuclear/classification

Leukocytes, Mononuclear/drug effects*


Middle Aged

Multiple Sclerosis, Relapsing-Remitting/drug therapy*

Multiple Sclerosis, Relapsing-Remitting/pathology*


Find related publications in this database (Keywords)

Multiple sclerosis
Beta-1 integrin
Adhesion molecule
Flow cytometry